Neuland Laboratories Ltd Reports 34% Increase in EBITDA in FY 2024-25

Neuland Laboratories Ltd, a leading pharmaceutical company, reported a 34% increase in EBITDA in the financial year 2024-25. The company's total income stood at INR 1,497 crore, with a profit after tax of INR 300 crore. The company also made significant strides in operational excellence, sustainability, and social responsibility. Neuland Laboratories was awarded the prestigious Sword of Honour by the British Safety Council and was featured in S&P’s Sustainability Yearbook for the second consecutive year.